Market Cap
$12.0M
PHIO
Phio Pharmaceuticals Corp.
$1.01 ▲ +0.99%
Prev close $1.00Market cap$12.0M
ConsensusStrong Buy
12-mo target$14.00 (+1286.3%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (3 insiders) Biotech & Drug Discovery
Snapshot
The big-picture read on PHIO right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
17 funds
Inst. Value
$608.6K
Inst. Activity
1 buys / 2 sells
Insider Activity
$69.0K buy / $0.00 sell
Insider Net $
$69.0K
Social Sentiment
43° Neutral
SEC Reports
5
Price chart 30d -10.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 Insider
Plott Ronald Todd bought 5,000 shares
Director @ $1.04 ($5.2K)
Sep 28, 2026 Insider
Bitterman Robert J was granted 400,000 shares
Chairman, Pres. & CEO
Sep 28, 2026 Insider
Sep 14, 2026 SEC Plott Ronald Todd was granted 17,000 shares
Director
Phio Pharmaceuticals announced a key development milestone for its lead siRNA candidate PH-762, submitting a meeting req
8-K — Impact 5/10
Phio Pharmaceuticals Corp. filed a DEFA14A (additional definitive proxy soliciting materials) for its 2026 Annual Meetin
DEFA14A — Impact 3/10
Aug 12, 2026 earnings_calendar
PHIO Q2 2026 Earnings Scheduled — 2026-08-12
Jun 30, 2026 Inst.
CITIGROUP INC — DOUBLED
11,605 shares ($11.9K)
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
5,387 shares ($5.5K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 7 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Price targets
Where 1 covering analysts think PHIO trades over the next 12 months.
$14.00 +1286.3% upside Strong Buy
Current$1.01 Low$14.00 Median$14.00 High$14.00 1 analysts
$14.00$14.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Social media sentiment mood +50.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 0 bearish, 1 mixed, 3 neutral · avg impact 4.8/10.
BULLISH8-K5/10
Phio Pharmaceuticals announced a key development milestone for its lead siRNA candidate PH-762, subm
Sep 14, 2026
NEUTRALDEFA14A3/10
Phio Pharmaceuticals Corp. filed a DEFA14A (additional definitive proxy soliciting materials) for it
Aug 14, 2026
NEUTRAL8-K5/10
Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to
Apr 8, 2026
NEUTRAL424B55/10
Phio Pharmaceuticals is conducting an at-the-market offering of up to $6.36 million in common stock
Apr 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 12, 2026
earnings_calendar
PHIO Q2 2026 Earnings Scheduled — 2026-08-12
Jul 15, 2026
short_volume
Short Volume: PHIO — 59.6% short (1.3M / 2.2M)
Short: 1,322,982 | Exempt: 277,931 | TRF Vol: 2,218,139 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
PHIO Q1 2026 Earnings Scheduled — 2026-05-13
Feb 12, 2026
short_interest
FTD: PHIO — 776,176 shares ($1.0M) failed to deliver
Settlement: 20260212, Price: $1.29, FTD Value: $1,001,267.04, PHIO PHARMACEUTICALS CORP COM
Feb 11, 2026
short_interest
FTD: PHIO — 2,311,187 shares ($2.6M) failed to deliver
Settlement: 20260211, Price: $1.12, FTD Value: $2,588,529.44, PHIO PHARMACEUTICALS CORP COM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.36 | $-0.37–$-0.35 | 18.2% | -2.9% | 0↑ 2↓ | $0.0B | 2 |
| Next Q | $-0.39 | $-0.40–$-0.37 | -156.7% | -4.1% | 0↑ 2↓ | $0.0B | 2 |
| Current FY | $-1.45 | $-1.47–$-1.42 | 0.3% | -1.8% | 0↑ 2↓ | $0.0B | 2 |
| Next FY | $-0.61 | $-0.77–$-0.45 | 57.8% | +3.2% | 2↑ 0↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.360 | — |
| 7d ago | $-0.360 | — |
| 30d ago | $-0.350 | -0.010 |
| 60d ago | $-0.325 | -0.035 |
| 90d ago | $-0.325 | -0.035 |
Institutional ownership
Which big funds own PHIO (from quarterly 13F filings) and who is adding or trimming.
17 institutional holders with $608.6K total value (607,194 shares) as of 2026-Q2. Top holders: JANE, GEODE, VANGUARD. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| JANE STREET GROUP, LLC | 117,755 | $120.7K | 19.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 114,574 | $117.4K | 19.3% | ADD +59.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 94,262 | $96.6K | 15.9% | — |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 50,000 | $51.0K | 8.4% | — |
| Cetera Investment Advisers | 47,500 | $48.7K | 8.0% | ADD +26.9% |
| CITADEL ADVISORS LLC | 47,150 | $48.3K | 7.9% | — |
| VANGUARD FIDUCIARY TRUST CO | 38,169 | $39.1K | 6.4% | — |
| NORTHERN TRUST CORP | 27,768 | $28.5K | 4.7% | — |
| TWO SIGMA INVESTMENTS, LP | 21,501 | $22.0K | 3.6% | — |
| CITIGROUP INC | 11,605 | $11.9K | 2.0% | DOUBLED +1032.2% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITIGROUP INC | DOUBLED | 1,025 | 11,605 | +1032.2% | $11.9K |
| UBS Group AG | NEAR_EXIT | 26,987 | 5,387 | -80.0% | $5.5K |
| HRT FINANCIAL LP | TRIM | 34,732 | 13,182 | -62.0% | $13.00 |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 92,638 | 147,254 | +59.0% | $179.6K |
| UBS Group AG | DOUBLED | 8,594 | 26,987 | +214.0% | $32.9K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 57,906 | 92,638 | +60.0% | $97.3K |
| Cetera Investment Advisers | ADD | 33,500 | 42,500 | +26.9% | $44.6K |
| UBS Group AG | DOUBLED | 13 | 8,594 | +66007.7% | $9.0K |
| VANGUARD GROUP INC | ADD | 48,665 | 87,628 | +80.1% | $217.3K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 46 | 1,400 | +2943.5% | $3.5K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 19 transactions. Net $69.0K — $69.0K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Plott Ronald Todd | Director | BUY | 5,000 | $1.04 | $5.2K |
| Sep 28, 2026 | Bitterman Robert J | Chairman, Pres. & CEO | AWARD | 400,000 | — | — |
| Sep 28, 2026 | Plott Ronald Todd | Director | AWARD | 17,000 | — | — |
| Sep 28, 2026 | Carson Lisa Cabott | Chief Financial Officer | AWARD | 108,000 | — | — |
| Sep 28, 2026 | Plott Ronald Todd | Director | BUY | 5,000 | $1.03 | $5.2K |
| Sep 24, 2026 | BRADFORD PATRICIA A | Director | BUY | 6,500 | $1.01 | $6.6K |
| Sep 22, 2026 | Bitterman Robert J | Chairman, Pres. & CEO | BUY | 2,000 | $1.03 | $2.1K |
| Sep 15, 2026 | BRADFORD PATRICIA A | Director | BUY | 12,000 | $1.03 | $12.4K |
| Sep 11, 2026 | Bitterman Robert J | Chairman, Pres. & CEO | TAX W/H | 68,550 | $1.03 | $70.6K |
| Sep 11, 2026 | Carson Lisa Cabott | Chief Financial Officer | TAX W/H | 12,888 | $1.03 | $13.3K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PHIO.
Shares short
149,890
Settlement Sep 15, 2026
Change vs prior
-32.3%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈1.3%
Estimate — not % of float
All PHIO filing & press-release reports (5)
- 8-K reportSep 14, 2026
- DEFA14A reportAug 14, 2026
- 8-K reportApr 8, 2026
- 424B5 reportApr 8, 2026
- 8-K reportMar 5, 2026